Literature DB >> 26340591

Human immunodeficiency virus and liver disease: An update.

Kenneth E Sherman1, Juergen Rockstroh2, David Thomas3.   

Abstract

UNLABELLED: Human immunodeficiency viral (HIV) infection affects approximately 1.2 million persons in the United States and 35 million worldwide. Progression to advanced liver disease remains a leading cause of death among HIV-infected persons in the United States and elsewhere. Though mortality from HIV complications has been dramatically reduced wherever effective combination antiretroviral therapy is used, there has been little impact on liver-related mortality. Causes of liver disease in the setting of HIV infection include viral hepatitis, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, drug-associated toxicities, and other metabolic/genetic disorders which interact in an environment modulated by persistent immune activation and altered cytokine display.
CONCLUSION: Despite significant advances in treatment of hepatitis C virus and suppression of hepatitis B virus, treatment and management principles for liver disease in HIV-infected patients remain challenging; limited resources, fragmented health care, and high levels of injection drug use, alcohol use, and depression remain relevant issues in the HIV-infected patient.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 26340591      PMCID: PMC4681629          DOI: 10.1002/hep.28150

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  73 in total

1.  Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria.

Authors:  Claudia Hawkins; Oche Agbaji; Placid Ugoagwu; Chloe L Thio; Muazu M Auwal; Charles Ani; Chinedum Okafo; Erika Wallender; Robert L Murphy
Journal:  Clin Infect Dis       Date:  2013-09-06       Impact factor: 9.079

2.  Trends in HIV diagnoses and testing among U.S. adolescents and young adults.

Authors:  H Irene Hall; Frances Walker; Daxa Shah; Eboni Belle
Journal:  AIDS Behav       Date:  2012-01

3.  Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

Authors:  Giada Sebastiani; Peter Ghali; Phil Wong; Marina B Klein; Marc Deschenes; Robert P Myers
Journal:  Can J Gastroenterol Hepatol       Date:  2014-01

Review 4.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Authors:  Philip Bruggmann; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

Review 5.  Integrating behavioral and biomedical research in HIV interventions: challenges and opportunities.

Authors:  Dianne M Rausch; Cynthia I Grossman; Emily J Erbelding
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

6.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Authors:  Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

7.  [Survival in patients with HIV infection].

Authors:  Nicolai Lohse; Ann-Brit Eg Hansen; Gitte Pedersen; Gitte Kronborg; Jan Gerstoft; Henrik Toft Sørensen; Michael Vaeth; Niels Obel
Journal:  Ugeskr Laeger       Date:  2007-06-25

Review 8.  Hepatitis E virus infection.

Authors:  Nassim Kamar; Jacques Izopet; Lionel Rostaing
Journal:  Curr Opin Gastroenterol       Date:  2013-05       Impact factor: 3.287

Review 9.  Is it HIV TTP or HIV-associated thrombotic microangiopathy?

Authors:  Mark E Brecher; Shauna N Hay; Yara A Park
Journal:  J Clin Apher       Date:  2008       Impact factor: 2.821

10.  Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.

Authors:  Margaret T May; Mark Gompels; Valerie Delpech; Kholoud Porter; Chloe Orkin; Stephen Kegg; Phillip Hay; Margaret Johnson; Adrian Palfreeman; Richard Gilson; David Chadwick; Fabiola Martin; Teresa Hill; John Walsh; Frank Post; Martin Fisher; Jonathan Ainsworth; Sophie Jose; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

View more
  24 in total

Review 1.  CROI 2016: Viral Hepatitis and Liver Fibrosis.

Authors:  Anne F Luetkemeyer; David L Wyles
Journal:  Top Antivir Med       Date:  2016 May-Jun

2.  PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals.

Authors:  Kenneth E Sherman; Susan D Rouster; Minhee Kang; Triin Umbleja; Richard Sterling; Adeel A Butt
Journal:  Dig Dis Sci       Date:  2018-09-14       Impact factor: 3.199

3.  Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.

Authors:  Kenneth E Sherman; Enass Abdel-Hameed; Susan D Rouster; Mohamed Tarek M Shata; Jason T Blackard; Parham Safaie; Barbara Kroner; Liliana Preiss; Paul S Horn; Shyam Kottilil
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

4.  Nevirapine-induced liver lipid-SER inclusions and other ultrastructural aberrations.

Authors:  Jayram Sastry; Heba Mohammed; Maria Mercedes Campos; Jack Uetrecht; Mones Abu-Asab
Journal:  Ultrastruct Pathol       Date:  2018-02-09       Impact factor: 1.094

5.  Adverse effects of antiretroviral therapy on liver hepatocytes and endothelium in HIV patients: An ultrastructural perspective.

Authors:  Sarah Chwiki; Maria Mercedes Campos; Mary E McLaughlin; David E Kleiner; Joseph A Kovacs; Caryn G Morse; Mones S Abu-Asab
Journal:  Ultrastruct Pathol       Date:  2017-02-28       Impact factor: 1.094

Review 6.  Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options.

Authors:  Sayed Sartaj Sohrab; Mohd Suhail; Ashraf Ali; Ishtiaq Qadri; Steve Harakeh; Esam I Azhar
Journal:  Virusdisease       Date:  2018-01-27

7.  Food insecurity is associated with magnetic resonance-determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV.

Authors:  Javier A Tamargo; Kenneth E Sherman; Adriana Campa; Sabrina S Martinez; Tan Li; Jacqueline Hernandez; Colby Teeman; Raul N Mandler; Jun Chen; Richard L Ehman; Marianna K Baum
Journal:  Am J Clin Nutr       Date:  2021-03-11       Impact factor: 8.472

8.  Long Noncoding RNAs Hepatocyte Nuclear Factor 4A Antisense RNA 1 and Hepatocyte Nuclear Factor 1A Antisense RNA 1 Are Involved in Ritonavir-Induced Cytotoxicity in Hepatoma Cells.

Authors:  Xiaofei Wang; Yihang Yu; Pei Wang; Kun Yang; Yiting Wang; Liang Yan; Xiao-Bo Zhong; Lirong Zhang
Journal:  Drug Metab Dispos       Date:  2021-12-23       Impact factor: 3.579

9.  Increased CD4 : CD8 ratio normalization with implementation of current ART management guidelines.

Authors:  Alice Zhabokritsky; Leah Szadkowski; Curtis Cooper; Mona Loutfy; Alexander Wong; Alison McClean; Robert S Hogg; Sharon L Walmsley
Journal:  J Antimicrob Chemother       Date:  2021-02-11       Impact factor: 5.790

Review 10.  Liver involvement in human immunodeficiency virus infection.

Authors:  Pankaj Puri; Sandeep Kumar
Journal:  Indian J Gastroenterol       Date:  2016-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.